JP2025506488A5 - - Google Patents
Info
- Publication number
- JP2025506488A5 JP2025506488A5 JP2024547510A JP2024547510A JP2025506488A5 JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5 JP 2024547510 A JP2024547510 A JP 2024547510A JP 2024547510 A JP2024547510 A JP 2024547510A JP 2025506488 A5 JP2025506488 A5 JP 2025506488A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- sequence identity
- identity
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202201674 | 2022-02-09 | ||
| GB2201674.5 | 2022-02-09 | ||
| GB2209454.4 | 2022-06-28 | ||
| GBGB2209454.4A GB202209454D0 (en) | 2022-06-28 | 2022-06-28 | Therapeutic antibodies |
| PCT/GB2023/050281 WO2023152486A1 (en) | 2022-02-09 | 2023-02-08 | Therapeutic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506488A JP2025506488A (ja) | 2025-03-11 |
| JP2025506488A5 true JP2025506488A5 (cg-RX-API-DMAC7.html) | 2026-01-30 |
Family
ID=85283675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547510A Pending JP2025506488A (ja) | 2022-02-09 | 2023-02-08 | 治療抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250340659A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4476256A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506488A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240139085A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023219227A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3258958A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002361A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024010901A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314314A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009898A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152486A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2560889A1 (en) * | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EA032389B1 (ru) * | 2012-02-14 | 2019-05-31 | Мериал, Инк. | Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン31モノクローナル抗体 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
-
2023
- 2023-02-08 WO PCT/GB2023/050281 patent/WO2023152486A1/en not_active Ceased
- 2023-02-08 MX MX2024009898A patent/MX2024009898A/es unknown
- 2023-02-08 US US18/837,256 patent/US20250340659A1/en active Pending
- 2023-02-08 KR KR1020247029746A patent/KR20240139085A/ko active Pending
- 2023-02-08 IL IL314314A patent/IL314314A/en unknown
- 2023-02-08 JP JP2024547510A patent/JP2025506488A/ja active Pending
- 2023-02-08 CA CA3258958A patent/CA3258958A1/en active Pending
- 2023-02-08 AU AU2023219227A patent/AU2023219227A1/en active Pending
- 2023-02-08 EP EP23706072.8A patent/EP4476256A1/en active Pending
-
2024
- 2024-08-07 CL CL2024002361A patent/CL2024002361A1/es unknown
- 2024-08-12 CO CONC2024/0010901A patent/CO2024010901A2/es unknown